Publicacións (149) Publicacións de MARIO DELGADO MORA

2022

  1. Editorial: The innate immune system in rheumatoid arthritis

    Frontiers in Immunology

2019

  1. Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in in vivo preclinical models of hematopoietic reconstitution and severe colitis

    Haematologica, Vol. 104, Núm. 2, pp. e54-e58

2014

  1. Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease

    Haematologica, Vol. 99, Núm. 7, pp. 1168-1175

2012

  1. NPSR1 gene is associated with reduced risk of rheumatoid arthritis

    Journal of Rheumatology, Vol. 39, Núm. 6, pp. 1166-1170

2009

  1. Adipose-Derived Mesenchymal Stem Cells Alleviate Experimental Colitis by Inhibiting Inflammatory and Autoimmune Responses

    Gastroenterology, Vol. 136, Núm. 3, pp. 978-989

  2. Generating tolerogenic dendritic cells with neuropeptides

    Human Immunology, Vol. 70, Núm. 5, pp. 300-307

  3. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis

    Gut, Vol. 58, Núm. 7, pp. 929-939

  4. Neuropeptides kill African trypanosomes by targeting intracellular compartments and inducing autophagic-like cell death

    Cell Death and Differentiation, Vol. 16, Núm. 3, pp. 406-416

  5. Requirement of IFN-γ-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells

    Tissue Engineering - Part A, Vol. 15, Núm. 10, pp. 2795-2806

  6. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells

    Arthritis and Rheumatism, Vol. 60, Núm. 4, pp. 1006-1019

2008

  1. Anti-inflammatory neuropeptides: A new class of endogenous immunoregulatory agents

    Brain, Behavior, and Immunity, Vol. 22, Núm. 8, pp. 1146-1151

  2. Emergence of cortistatin as a new immunomodulatory factor with therapeutic potential in immune disorders

    Molecular and Cellular Endocrinology, Vol. 286, Núm. 1-2, pp. 135-140

  3. Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: A new therapeutic approach for immune disorders

    Journal of Cellular and Molecular Medicine, Vol. 12, Núm. 5B, pp. 1830-1847

  4. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: Altered expression and signal in immune cells

    Arthritis and Rheumatism, Vol. 58, Núm. 4, pp. 1010-1019

  5. Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria

    Journal of Immunology, Vol. 180, Núm. 12, pp. 8369-8377

  6. Immunotherapy for neurological diseases

    Clinical Immunology

  7. In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis

    Arthritis and Rheumatism, Vol. 58, Núm. 4, pp. 1026-1037

  8. Modulation of established murine collagen-induced arthritis by a single inoculation of short-term lipopolysaccharide-stimulated dendritic cells

    Annals of the Rheumatic Diseases, Vol. 67, Núm. 9, pp. 1235-1241

  9. N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: Randomized, placebo-controlled pilot study

    World Journal of Gastroenterology, Vol. 14, Núm. 18, pp. 2851-2857

  10. Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1

    American Journal of Pathology, Vol. 172, Núm. 5, pp. 1297-1302